Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 811-815

  Lee, Ding Jen ^a   Trotti, Andy ^b   Spencer, Sharon ^c   Rostock, Robert ^d   Fisher, Cheryl ^e   Von Roemeling, Reinhard ^e   Harvey, Elizabeth ^e   Groves, Eric ^e  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Wyoming Valley Cancer Center   (United States)

^e Sanofi Winthrop Inc   (United States)

Author keywords

Head and neck carcinoma; Hypoxic cytotoxin; SR 4233; Tirapazamine

Indexed keywords

RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TRIAZINES;

EID: 0031743190     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00310-1     Document Type: Conference Paper

References (22)

1. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
2. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 9:1955;539-549.
3. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastasis and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 14:1988;831-838.
4. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:1997;285-289.
5. Fazekas J.T., Pajak T.F., Wasserman T., et al. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys. 13:1987;1155-1160.
6. Overgaard J., Hansen H.S., Anderson A.P., et al. Misonidazole combined with split course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx Report from the DAHANCA study . Int J Radiat Oncol Biol Phys. 16:1989;1065-1068.
7. Overgaard J., Hansen H.S., Lindelov B., et al. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharyngeal carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol. 20:(Suppl.):1991;143-149.
8. Chassagne D., Charreau I., Sancho-Garnier H., et al. First analysis on tumor regression for the European Randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys. 22:1992;581-584.
9. Lee D.J., Cosmatos D., Marcial V.A., et al. Results of an RTOG Phase III Trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys. 32:1995;567-576.
10. Van den Bogaert W., Van der Schueren E., Hoirot J.C., et al. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: Long term results and side effects. Radiother Oncol. 35:1995;91-99.
11. Brown J.M., Lemmon M.J. Potentiation by hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:1990;7745-7749.
12. Brown J.M. SR 4233 (Tirapazamine) A new anticancer drug exploiting hypoxia in solid tumors . Br J Cancer. 67:1993;1163-1170.
13. Dorie M.J., Brown J.M. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 39:1997;361-366.
14. Hall E. Radiosensitizers and bioreductive drugs. Hall E. Radiobiology for the radiologist. 4th ed. 1994;165-178 Lippincott, Philadelphia.
15. Workman P. Keynote address Bioreductive mechanisms . Int J Radiat Oncol Biol Phys. 22:1992;631-637.
16. Hancock SL, Mariscal M, Spencer S; et al. Clinical evaluation of the hypoxic cytotoxin tirapazamine (SR 4233) with fractionated irradiation: Phase 1 experience at Stanford University and the University of Alabama (abstract). Conference abstracts, Ninth International Conference on Chemical Modifiers of Cancer Treatment; 1995 Aug 22-26; Oxford, U.K.
17. Buswell L, Riese N, Shulman L; et al. A phase I study of the hypoxic cell cytotoxin tirapazamine (SR 4233) with concurrent radiation therapy (Abstract). Conference abstracts, Ninth International Conference on Chemical Modifiers of Cancer Treatment; 1995 Aug 22-26; Oxford, U.K.
18. Doherty N., Hancock S.L., Kaye S., et al. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys. 29:1994;379-382.
19. Manual for staging of cancer. 4th ed. 1992;AJCC, Chicago.
20. Henk J.M., Kunkler P.B., Smith C.W. Radiotherapy and hyperbaric oxygen in head and neck cancer Final report of first controlled clinical trial . Lancet. ii:1977;101-103.
21. Henk J.M., Smith C.W. Radiotherapy and hyperbaric oxygen in head and neck cancer Interim report of second clinical trial . Lancet. ii:1977;104-105.
22. Brown J.M. Hypoxic cell radiosensitization: The end of an era? Regarding Lee; et al. IJROBP 32:567-576 [editorial]. Int J Radiat Oncol Biol Phys. 32:1995;883-885.